SummitTX Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

SummitTX Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,231	Closed	-$3.28M	–	989
2025 Q4	$3.28M	Sell	7,231 -724	-9%	-$312K	0.1%	217
2025 Q3	$3.12M	Buy	+7,955	New	+$3.32M	0.13%	180
2025 Q2	–	Sell	-11,743	Closed	-$5.69M	–	1025
2025 Q1	$5.69M	Buy	+11,743	New	+$5.47M	0.25%	99

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

SummitTX Capital's VRTX Position: Q1 2026 in Review

SummitTX Capital sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 7,231 shares — an estimated $3.28M sold.

SummitTX Capital first reported a position in VRTX in Q1 2025 and held it in 3 quarters. The position peaked at $5.69M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

SummitTX Capital reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
SummitTX Capital sold 7,231 Vertex Pharmaceuticals shares in Q1 2026, an estimated $3.28M.
SummitTX Capital first reported a position in Vertex Pharmaceuticals in Q1 2025 and held it in 3 quarters.
SummitTX Capital's Vertex Pharmaceuticals position peaked at $5.69M in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.